Beta-Caryophyllene / Dose Cancer Research Results

BCP, Beta-Caryophyllene: Click to Expand ⟱
Features:

β-Caryophyllene is a dietary sesquiterpene and CB2 agonist with preclinical anticancer evidence, including apoptosis induction, reduced proliferation, anti-angiogenesis, reduced invasion/migration, and chemo/radio-sensitization. Evidence is promising but remains mainly in-vitro and animal-based; clinical cancer validation is lacking.
-naturally occurring sesquiterpene found in many plant essential oils: black pepper, clove oil ...

Beta-Caryophyllene — β-Caryophyllene is a plant-derived bicyclic sesquiterpene hydrocarbon and dietary cannabinoid with selective functional agonism at cannabinoid receptor type 2. It is formally classified as a natural sesquiterpene terpene, food flavoring compound, and investigational phytochemical adjunct rather than an approved anticancer drug. Standard abbreviations include BCP, β-CP, and sometimes trans-caryophyllene. It occurs in multiple essential oils, especially black pepper, clove, copaiba, oregano, hops, rosemary, and Cannabis sativa chemotypes, but its database identity should be the purified compound rather than a whole-oil product.

Primary mechanisms (ranked):

  1. CB2-centered anti-inflammatory and immunomodulatory signaling, with low CB1 activity and therefore no intrinsic THC-like psychoactive classification.
  2. Suppression of pro-survival oncogenic signaling, especially PI3K/Akt/mTOR, STAT3, NF-κB, and related proliferation or survival pathways in cancer models.
  3. Induction of mitochondrial apoptosis through Bax/Bcl-2 shift, caspase activation, mitochondrial stress, and cell-cycle arrest in several cancer cell lines.
  4. Anti-angiogenic and anti-migratory activity, including inhibition of endothelial migration, tube formation, VEGF-linked responses, EMT, invasion, and metastasis-associated phenotypes.
  5. Chemosensitization, mainly preclinical, reported with cisplatin and other cytotoxic or targeted agents; mechanism appears context-dependent and partly linked to apoptosis and resistance-pathway modulation.
  6. Radiosensitization, currently preliminary and model-dependent, with recent colorectal cancer cell evidence involving PPARγ-mediated apoptosis.
  7. ROS/NRF2 modulation is secondary and context-dependent: BCP can promote oxidative stress in cancer-cell apoptosis models, while in normal injury models it more often shows cytoprotective antioxidant and NRF2-linked effects.

Bioavailability / PK relevance: BCP is highly lipophilic and formulation-sensitive; oral exposure is limited and variable with conventional dosing, while self-emulsifying lipid formulations can substantially improve human systemic exposure. PK relevance is high because many in-vitro anticancer concentrations are unlikely to be reproduced by normal dietary intake.

Delivery constraints: The key delivery constraints are volatility, hydrophobicity, oxidation/stability, low aqueous solubility, food-matrix dependence, and the likely need for lipid, nanoemulsion, SEDDS, or other formulation strategies if systemic pharmacology is the goal.

In-vitro vs systemic exposure relevance: Most anticancer assays use micromolar-to-high-micromolar or µg/mL concentrations; these should be interpreted cautiously because common in-vitro levels likely exceed exposures achievable from culinary intake. Formulated oral BCP may improve exposure, but clinical anticancer target engagement has not been established.

Clinical evidence status: Preclinical oncology evidence is moderate and spans cell, endothelial, and animal models; human evidence is small and mostly non-oncology or PK-focused. No validated clinical cancer efficacy evidence was found. Best database status is preclinical / investigational adjunct, with possible chemosensitizer and anti-angiogenic tags marked as preclinical.

Beta-Caryophyllene Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 CB2 receptor signaling CB2 engagement may shift inflammatory and survival signaling ↓ (context-dependent) CB2-mediated inflammation ↓ with low CB1 psychoactivity R/G Anti-inflammatory and immunomodulatory signaling Core pharmacologic identity of BCP; direct anticancer dependence on CB2 varies by model.
2 PI3K Akt mTOR STAT3 survival signaling PI3K/Akt/mTOR ↓; STAT3 ↓; proliferation ↓; survival ↓ Usually cytoprotective or neutral at lower exposure (context-dependent) R/G Growth suppression and apoptosis sensitization Central anticancer axis across bladder, ovarian, lung, and other cell models; not yet clinically validated.
3 Mitochondrial apoptosis Bax ↑; Bcl-2 ↓; caspase-3 ↑; mitochondrial stress ↑; apoptosis ↑ In injury models, mitochondrial dysfunction often ↓ G Intrinsic apoptotic cell death Strong recurring preclinical mechanism; cancer selectivity depends on dose and model.
4 Angiogenesis and endothelial migration VEGF-linked angiogenesis ↓; invasion ↓; migration ↓ Endothelial migration and tube formation ↓ (model-dependent) G Anti-angiogenic and anti-metastatic pressure Important for colorectal xenograft and endothelial assay interpretation; may be therapeutically relevant but exposure-limited.
5 NF-κB inflammatory signaling NF-κB-linked survival and cytokine tone ↓ (context-dependent) Inflammatory cytokine signaling ↓ R/G Inflammation-linked tumor support reduction More robust as an anti-inflammatory mechanism than as a standalone cancer-killing mechanism.
6 ROS and mitochondrial oxidative stress ROS ↑ can contribute to apoptosis (high concentration only) Oxidative stress ↓ in many toxic injury models R/G Context-dependent redox modulation antioxidant or pro-oxidant; direction depends on cell type, injury context, and concentration.
7 NRF2 cytoprotection ↔ or context-dependent; may be undesirable if it protects malignant cells NRF2/HO-1/NQO1 ↑ in injury-protection models G Secondary antioxidant-response modulation NRF2 is not a core anticancer mechanism for BCP; tag as secondary/contextual rather than primary.
8 Chemosensitization Cisplatin response ↑; apoptosis ↑; resistance signaling ↓ (model-dependent) Normal-cell toxicity data are insufficient for oncology combinations G Adjunct sensitization Preclinical evidence supports a sensitizer hypothesis, but there is no clinical cancer validation.
9 Radiosensitization Radiation response ↑ in colorectal cancer cells (model-dependent) Normal-tissue radioprotection versus radiosensitization is unresolved G Potential radiation adjunct Recent evidence is early and should be tagged as preliminary, not established.
10 Glycolysis and HIF-1α ↔ limited direct oncology evidence ↔ not a primary established axis G Not a core mechanism Do not add strong HIF-1α or glycolysis tags unless future product-specific cancer evidence supports them.
11 Clinical Translation Constraint Effective in-vitro exposure may exceed practical dietary exposure Food-use safety does not establish therapeutic-dose safety G PK and evidence limitation Key constraints are bioavailability, formulation, dose, tissue exposure, cancer-type heterogeneity, and lack of oncology trials.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
Dose, Dosage: Click to Expand ⟱
Source:
Type:
Drug dosage vs efficacy, and actual dosage number of research papers.
Scientific Papers found: Click to Expand⟱
6391- Eug,  BCP,  5-FU,    Exploring Mechanism of Actions for Eugenol and Beta-Caryophyllene to Combat Colorectal Cancer Chemotherapy Using Network Pharmacology
- in-vitro, CRC, HCT116
eff↑, ChemoSen↑, HSP90↓, Dose↝, TumAuto↑, Apoptosis↑, PI3K↓, Akt↓, mTOR↓, JNK↓, p38↓, EMT↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 1,   JNK↓, 1,   p38↓, 1,  

Protein Folding & ER Stress ⓘ

HSP90↓, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,   mTOR↓, 1,   PI3K↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   Dose↝, 1,   eff↑, 1,  
Total Targets: 12

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Dose, Dosage
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:401  Target#:1114  State#:%  Dir#:4
  wNotes=0  sortOrder:rid,rpid

 

Home Page